Fig. 2: Treatment algorithm for newly-diagnosed acute myeloid leukemia in patients unfit for venetoclax-hypomethylating agent.
From: Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms
Targeted inhibitors = FLT3, IDH1/2 or menin inhibitor. Ven-Venetoclax, HMA- hypomethylating agent- azacitidine (I/V or S/C), decitabine (I/V or PO). *Consider sequential therapy with ivosidenib or enasidenib + azacitidine in select situations.
